Veppanu is a drug owned by Arvinas Operations Inc. It is protected by 3 US drug patents filed in 2026 out of which none have expired yet. Veppanu's patents will be open to challenges from 01 May, 2030. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 30, 2038. Details of Veppanu's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US10647698 | Tetrahydronaphthalene And Tetrahydroisoquinoline Derivatives As Estrogen Receptor Degraders |
Jan, 2038
(11 years from now) | Active |
| US11597720 | Tetrahydronaphthalene And Tetrahydroisoquinoline Derivatives As Estrogen Receptor Degraders |
Dec, 2037
(11 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10899742 | NA |
Dec, 2037
(11 years from now) | Active |
FDA has granted several exclusivities to Veppanu. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Veppanu, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Veppanu.
Exclusivity Information
Veppanu holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Veppanu's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 01, 2031 |
US patents provide insights into the exclusivity only within the United States, but
Veppanu is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Veppanu's family patents as well as insights into
ongoing legal events
on those patents.
Veppanu's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Veppanu's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 30, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Veppanu Generics:
There are no approved generic versions for Veppanu as of now.
About Veppanu
Veppanu is a drug owned by Arvinas Operations Inc. Veppanu uses Vepdegestrant as an active ingredient. Veppanu was launched by Arvinas Operations in 2026.
Approval Date:
Veppanu was approved by FDA for market use on 01 May, 2026.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Veppanu is 01 May, 2026, its NCE-1 date is estimated to be 01 May, 2030.
Active Ingredient:
Veppanu uses Vepdegestrant as the active ingredient. Check out other Drugs and Companies using Vepdegestrant ingredient
Dosage:
Veppanu is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 200MG | TABLET | Prescription | ORAL |
| 100MG | TABLET | Prescription | ORAL |